Annual Accounts Receivable
$923.00 K
-$2.75 M-74.90%
31 December 2023
Summary:
Sangamo Therapeutics annual accounts receivable is currently $923.00 thousand, with the most recent change of -$2.75 million (-74.90%) on 31 December 2023. During the last 3 years, it has fallen by -$4.30 million (-82.33%). SGMO annual accounts receivable is now -97.50% below its all-time high of $36.91 million, reached on 31 December 2019.SGMO Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$10.50 M
+$9.91 M+1706.54%
30 September 2024
Summary:
Sangamo Therapeutics quarterly accounts receivable is currently $10.50 million, with the most recent change of +$9.91 million (+1706.54%) on 30 September 2024. Over the past year, it has increased by +$9.35 million (+814.29%). SGMO quarterly accounts receivable is now -73.42% below its all-time high of $39.49 million, reached on 30 September 2020.SGMO Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SGMO Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -74.9% | +814.3% |
| 3 y3 years | -82.3% | +31.7% |
| 5 y5 years | -80.3% | -52.2% |
SGMO Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -84.7% | at low | at high | +1706.5% |
| 5 y | 5 years | -97.5% | at low | -73.4% | +1706.5% |
| alltime | all time | -97.5% | +1237.7% | -73.4% | >+9999.0% |
Sangamo Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $10.50 M(+1706.5%) |
| June 2024 | - | $581.00 K(-15.9%) |
| Mar 2024 | - | $691.00 K(-25.1%) |
| Dec 2023 | $923.00 K(-74.9%) | $923.00 K(-19.6%) |
| Sept 2023 | - | $1.15 M(-57.7%) |
| June 2023 | - | $2.72 M(-61.3%) |
| Mar 2023 | - | $7.03 M(+91.0%) |
| Dec 2022 | $3.68 M(-38.8%) | $3.68 M(-18.7%) |
| Sept 2022 | - | $4.52 M(-24.7%) |
| June 2022 | - | $6.00 M(-13.5%) |
| Mar 2022 | - | $6.94 M(+15.4%) |
| Dec 2021 | $6.01 M(+15.1%) | $6.01 M(-24.5%) |
| Sept 2021 | - | $7.97 M(+15.8%) |
| June 2021 | - | $6.88 M(+2.0%) |
| Mar 2021 | - | $6.75 M(+29.1%) |
| Dec 2020 | $5.22 M(-85.8%) | $5.22 M(-86.8%) |
| Sept 2020 | - | $39.49 M(+602.9%) |
| June 2020 | - | $5.62 M(-19.4%) |
| Mar 2020 | - | $6.97 M(-81.1%) |
| Dec 2019 | $36.91 M(+689.8%) | $36.91 M(+68.1%) |
| Sept 2019 | - | $21.95 M(+81.5%) |
| June 2019 | - | $12.10 M(+65.4%) |
| Mar 2019 | - | $7.31 M(+56.5%) |
| Dec 2018 | $4.67 M(+39.8%) | $4.67 M(-16.1%) |
| Sept 2018 | - | $5.57 M(+11.9%) |
| June 2018 | - | $4.98 M(+39.2%) |
| Mar 2018 | - | $3.58 M(+6.9%) |
| Dec 2017 | $3.34 M(-32.8%) | $3.34 M(-2.6%) |
| Sept 2017 | - | $3.43 M(-1.8%) |
| June 2017 | - | $3.50 M(+45.6%) |
| Mar 2017 | - | $2.40 M(-51.7%) |
| Dec 2016 | $4.97 M(+97.2%) | $4.97 M(+235.5%) |
| Sept 2016 | - | $1.48 M(-35.7%) |
| June 2016 | - | $2.31 M(-10.2%) |
| Mar 2016 | - | $2.57 M(+1.8%) |
| Dec 2015 | $2.52 M(-75.7%) | $2.52 M(-64.0%) |
| Sept 2015 | - | $7.00 M(+35.2%) |
| June 2015 | - | $5.18 M(-22.0%) |
| Mar 2015 | - | $6.64 M(-36.0%) |
| Dec 2014 | $10.37 M(+228.6%) | $10.37 M(+22.4%) |
| Sept 2014 | - | $8.47 M(+21.6%) |
| June 2014 | - | $6.97 M(+30.0%) |
| Mar 2014 | - | $5.36 M(+69.9%) |
| Dec 2013 | $3.15 M(-23.6%) | $3.15 M(-35.3%) |
| Sept 2013 | - | $4.88 M(-0.8%) |
| June 2013 | - | $4.92 M(+34.1%) |
| Mar 2013 | - | $3.67 M(-11.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $4.13 M(+349.3%) | $4.13 M(+17.8%) |
| Sept 2012 | - | $3.50 M(+8.1%) |
| June 2012 | - | $3.24 M(+114.9%) |
| Mar 2012 | - | $1.51 M(+64.1%) |
| Dec 2011 | $919.00 K(+151.1%) | $919.00 K(-20.3%) |
| Sept 2011 | - | $1.15 M(-16.5%) |
| June 2011 | - | $1.38 M(-6.1%) |
| Mar 2011 | - | $1.47 M(+301.6%) |
| Dec 2010 | $366.00 K(+430.4%) | $366.00 K(-23.9%) |
| Sept 2010 | - | $481.00 K(+83.6%) |
| June 2010 | - | $262.00 K(+83.2%) |
| Mar 2010 | - | $143.00 K(+107.2%) |
| Dec 2009 | $69.00 K(-86.2%) | $69.00 K(-95.0%) |
| Sept 2009 | - | $1.39 M(>+9900.0%) |
| June 2009 | - | $13.00 K(-98.5%) |
| Mar 2009 | - | $863.00 K(+72.6%) |
| Dec 2008 | $500.00 K(+139.2%) | $500.00 K(-94.3%) |
| Sept 2008 | - | $8.79 M(-2.1%) |
| June 2008 | - | $8.98 M(+1364.6%) |
| Mar 2008 | - | $613.00 K(+193.3%) |
| Dec 2007 | $209.00 K(-57.1%) | $209.00 K(+945.0%) |
| Sept 2007 | - | $20.00 K(-87.5%) |
| June 2007 | - | $160.00 K(-27.3%) |
| Mar 2007 | - | $220.00 K(-54.8%) |
| Dec 2006 | $487.00 K(-49.8%) | $487.00 K(+78.4%) |
| Sept 2006 | - | $273.00 K(+19.7%) |
| June 2006 | - | $228.00 K(-21.9%) |
| Mar 2006 | - | $292.00 K(-69.9%) |
| Dec 2005 | $971.00 K(+70.7%) | $971.00 K(+967.0%) |
| Sept 2005 | - | $91.00 K(-59.9%) |
| June 2005 | - | $227.00 K(+0.4%) |
| Mar 2005 | - | $226.00 K(-60.3%) |
| Dec 2004 | $569.00 K(-13.5%) | $569.00 K(+240.7%) |
| Sept 2004 | - | $167.00 K(-50.0%) |
| June 2004 | - | $334.00 K(+41.5%) |
| Mar 2004 | - | $236.00 K(-64.1%) |
| Dec 2003 | $658.00 K(-40.1%) | $658.00 K(+335.8%) |
| Sept 2003 | - | $151.00 K(0.0%) |
| June 2003 | - | $151.00 K(-83.3%) |
| Mar 2003 | - | $904.00 K(-17.7%) |
| Dec 2002 | $1.10 M(+43.9%) | $1.10 M(+51.7%) |
| Sept 2002 | - | $724.00 K(+161.4%) |
| June 2002 | - | $277.00 K(-25.9%) |
| Mar 2002 | - | $374.00 K(-51.0%) |
| Dec 2001 | $763.00 K | $763.00 K(-34.7%) |
| Sept 2001 | - | $1.17 M(-15.7%) |
| June 2001 | - | $1.39 M(-36.7%) |
| Mar 2001 | - | $2.19 M |
FAQ
- What is Sangamo Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Sangamo Therapeutics?
- What is Sangamo Therapeutics annual accounts receivable year-on-year change?
- What is Sangamo Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Sangamo Therapeutics?
- What is Sangamo Therapeutics quarterly accounts receivable year-on-year change?
What is Sangamo Therapeutics annual accounts receivable?
The current annual accounts receivable of SGMO is $923.00 K
What is the all time high annual accounts receivable for Sangamo Therapeutics?
Sangamo Therapeutics all-time high annual accounts receivable is $36.91 M
What is Sangamo Therapeutics annual accounts receivable year-on-year change?
Over the past year, SGMO annual accounts receivable has changed by -$2.75 M (-74.90%)
What is Sangamo Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of SGMO is $10.50 M
What is the all time high quarterly accounts receivable for Sangamo Therapeutics?
Sangamo Therapeutics all-time high quarterly accounts receivable is $39.49 M
What is Sangamo Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, SGMO quarterly accounts receivable has changed by +$9.35 M (+814.29%)